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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To determine the effects of various disease-modifying treatment modalities in people with autoimmune haemolytic anaemia.
B A C K G R O U N D
Description of the condition
Autoimmune haemolytic anaemia (AIHA) is a condition charac-
terised by the presence of autoantibodies which bind to surface
of the patient’s own red blood cells (RBCs) leading to premature
destruction (Gehrs 2002). Such destruction of RBCs (haemoly-
sis) can occur within the circulation (intravascular haemolysis) or
within the spleen (extravascular haemolysis). Incidence of AIHA
ranges from 0.8 to 3 new cases per 100,000 individuals per year,
and the estimated prevalence is 17 per 100,000 individuals, more
commonly occurring in individuals after 50 years of age (Aladjidi
2011; Eaton 2007; Gehrs 2002; Klein 2010; Sokol 1992). AIHA
may run an acute or chronic course; severity of the condition can
range from fully compensated disease to life-threatening anaemia,
and can be classified by the temperature reactivity of RBC autoan-
tibodies, as well as by the underlying aetiology. Warm AIHA is
the most common type; it is associated with autoantibodies, often
immunoglobulin G (IgG), being most reactive at 37oC and can be
secondary to rheumatological disorders and lymphoproliferative
conditions. Haemolysis is usually extravascular and takes place in
the spleen, with a disease course that is typically chronic and re-
lapsing. Cold AIHA, on the other hand, is a result of autoantibod-
ies, usually immunoglobulin M (IgM), with the highest affinity
at 0oC to 4oC and can be associated with underlying lympho-
proliferative conditions and infections (e.g. mycoplasma, Ebstein-
Barr virus). IgM causes complement fixation and results in in-
travascular haemolysis, which tends to be abrupt but self-limiting.
Paroxysmal cold haemoglobinuria is a rare subtype of cold AIHA
caused by IgG that preferentially binds at a lower temperature,
mostly in children following infections. Infrequently, mixed-type
AIHA may occur in an individual where a combination of warm
and cold autoantibodies exist. Drug-induced immune haemolytic
anaemia (DIIHA) is a distinct entity that may be associated with
both warm and cold AIHA (Johnson 2007). This review will fo-
cus on the treatment for primary, or idiopathic AIHA, where no
underlying systemic disease can be identified.
Diagnosis of primary AIHA depends on the demonstration of
haemolysis, serologic evidence of autoantibody against patients’
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own RBCs and exclusion of secondary causes (identifiable in
20% to 80% of cases) (Gehrs 2002). The direct antiglobulin
test (DAT) is commonly used to demonstrate the presence of
autoantibody-coated patient RBCs, although it is important to
bear in mind alternative causes for a positive DAT including the
use of intravenous immunoglobulin, drug-induced autoantibod-
ies, haemolytic transfusion reaction, thalassaemia, sickle cell dis-
ease, and multiple myeloma (Clark 1992). Haemolysis on the
other hand, is suggested clinically when yellowish discolouration
of the skin (jaundice), together with pallor is detected with or
without the presence of enlargement of the spleen (splenomegaly).
In terms of laboratory evaluation, complete blood count with pe-
ripheral smear, serum bilirubin, lactate dehydrogenase (LDH),
haptoglobin, methaemalbumin and urine haemoglobin are use-
ful in determining the presence and type of haemolysis (pres-
ence of schistocytes, lowhaptoglobin, raisedmethaemalbumin and
urine haemoglobin in intravascular haemolysis; presence of sphe-
rocytes, raised unconjugated bilirubin in extravascular haemoly-
sis). In warm AIHA, anti-IgG anti-sera is typically detected in
DAT while in cold AIHA, anti-C3d anti-sera is usually present
due to IgM-mediated haemolysis.
Individuals with AIHA may required immunomodulatory thera-
pies and a proportion of them, especially those with severe anaemia
and mixed serological type, may require multiple agents to achieve
treatment response (Barcellini 2014). They also experience mor-
bidities and mortality due to the use of immunomodulatory ther-
apies including splenectomy. Between a quarter and half of all
individuals who achieve remission might develop disease relapse
(Barcellini 2014). Non-responders or those who relapse may be
dependent on regular transfusions to alleviate the symptoms of
anaemia.
Description of the intervention
Treatment depends on the severity of haemolysis. Supportive treat-
ment including folic acid supplementation, red cell transfusion
and avoidance of cold exposure in individuals with cold AIHA are
not within the scope of the current review (Gehrs 2002). In AIHA
with identifiable secondary causes, treatment should be targeted
towards the underlying condition.
Specific treatment for idiopathic AIHA includes immunosuppres-
sive or immunomodulatory therapy. Traditionally, glucocorticoids
(prednisolone 1 mg to 1.5 mg/kg/day for one to three weeks then
tapered) are the first-line therapy for patients with AIHA with up
to three quarters of patients demonstrating improvement within
three weeks. Relapse is nevertheless common (15% to 40%) after
tapering of glucocorticoids in the first six months to one year, and
thus the majority of patients responding to glucocorticoids would
have to be continued with a lower maintenance dose (Aladjidi
2011; Sankaran 2016; Zanella 2014). Adverse effects from pro-
longed glucocorticoid use include Cushingoid changes, hyperten-
sion, hyperglycaemia, peptic ulcers, and reduced bone mineral
density. Splenectomy has been considered the second-line ther-
apy for patients failing glucocorticoid therapy. Response rates af-
ter splenectomy ranged from 60% to 75%, but carry the risk of
thrombosis as well as infection due to encapsulated bacteria and
parasites including malaria (Davidson 2001; Katkhouda 1998).
In patients with refractory disease, a number of interventions
have been tested with various degree of success. These include
immunosuppressive agents including cyclophosphamide, dana-
zol, cyclosporine, and mycophenolate mofetil (Hershko 1990;
Howard 2002; Moyo 2002; Pignon 1993), as well as mon-
oclonal antibodies including anti-CD20 (rituximab) and anti-
CD52 (alemtuzumab) (Zecca 2003; Cheung 2006). With a re-
sponse rate of 80% to 90%, rituximab is increasingly being used in
AIHA patients failing glucocorticoids. Each medication possesses
its own side effects which are detailed in the next section. (Cheung
2006; Hershko 1990; Howard 2002; Moyo 2002; Pignon 1993,
Zecca 2003), Interventions targeted at removing circulating au-
toantibodies include intravenous immunoglobulin and plasma ex-
change (Flores 1993; Smith 2003). Accessibility to the above mea-
sures may be limited in resource-poor countries.
How the intervention might work
Immunosuppressive or immunomodulatory therapy interferewith
the immune destruction of RBCs
1. Glucocorticoids inhibit Fc receptor-mediated removal of
sensitised RBCs, and in the longer term reduce production of
autoantibodies (Zanella 2014).
2. Splenectomy removes a major site of RBC destruction and
autoantibody production (Zanella 2014).
3. Rituximab is an anti-CD20 monoclonal antibody given as
four weekly intravenous infusions. The antibody targets and
depletes host B cells, which are responsible for the generation of
autoantibodies (Zecca 2003). Side effects include infusion
reactions, immunosuppression and hepatitis B reactivation.
4. Alemtuzumab is an anti-CD52 monoclonal antibody
targeting CD52, which is an antigen expressed by mature
lymphocytes. Lymphodepletion with alemtuzumab would
effectively devoid the host’s capability of autoantibody
generation (Cheung 2006). Side effects include infusion
reactions and immunosuppression.
5. Cyclophosphamide is an alkylating agent with potent
myelosuppressive effect. Lymphocytes are highly sensitive to the
drug and depletion would disrupt the autoimmunity involved
(Moyo 2002). Nausea, vomiting, alopecia, myelosuppression,
haemorrhagic cystitis, and gonadal toxicity are potential adverse
effects with the drug.
6. Danazol is a semi-synthetic androgen with
immunomodulatory effect via decreasing IgG production and
cell-bound IgG and complement (Pignon 1993). Side effects
include its androgenic effects and derangement in liver function.
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7. Cyclosporine is a calcineurin inhibitor that suppresses T
helper cells activities, decreasing autoantibodies synthesis
(Hershko 1990). Patients should be monitored for hair growth,
gum hypertrophy, renal impairment, hypertension and rarely,
neurological complications.
8. Mycophenolate mofetil reversibly inhibits inosine
monophosphate dehydrogenase and in turn inhibits purine
synthesis required in the proliferation of B and T cells (Howard
2002). Adverse effects are gastrointestinal disturbances and
myelosuppression.
9. Use of intravenous immunoglobulin in AIHA is based on
its effectiveness in immune thrombocytopenia, but its efficacy
with AIHA is more controversial. The mechanism of action is
hypothesised to be through competitive inhibition of
autoantibody adsorption to patient blood cells, as well as by
decreasing uptake of autoantibody-coated blood cells by the
reticuloendothelial system through blockage of macrophage Fc
receptors (Flores 1993). Infusion reactions, fever, arthralgia,
haemolysis, and aseptic meningitis are possible complications.
10. Plasma exchange is usually reserved for patients with
fulminant AIHA. The process effectively removes host
circulating immunoglobulins and complements that are
responsible for the immune destruction of RBCs (Smith 2003).
Side effects are attributed to the insertion of the apheresis
catheter, and the process of apheresis which may cause
haemodynamic disturbances, hypocalcaemia and coagulopathy.
Why it is important to do this review
Various immunosuppressive medications and other specific treat-
ment modalities are available for the management of idiopathic
AIHA. As an uncommon condition, it remains uncertain whether
high-quality evidence exists to support any treatment regimen and
what the most effective regimen is, in particular for relapsing or
refractory disease. This systematic review will provide an evidence
base for the selection of immunomodulatory treatment that most
likely benefits people with idiopathic AIHA.
O B J E C T I V E S
To determine the effects of various disease-modifying treatment
modalities in people with autoimmune haemolytic anaemia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will only include randomised controlled trials (RCTs).
Types of participants
We will include people of both genders and all ages suffering from
idiopathic AIHA. Individuals with newly diagnosed, relapsing or
refractory disease; warm or cold AIHA will be included. Studies
on patients with secondary AIHA will be excluded.
Types of interventions
We will include trials evaluating specific, immunosuppressive or
immunomodulatory treatments for AIHA, including but not lim-
ited to: corticosteroids, intravenous immunoglobulin (IVIG), rit-
uximab, alemtuzumab, azathioprine, cyclosporine, mycopheno-
late mofetil (MMF), plasma exchange and splenectomy. We will
exclude trials of supportive treatment such as folic acid supple-
ment and transfusion alone. The control interventions can be an-
other specific treatment or placebo treatment or supportive treat-
ment alone, or no treatment.We will also include trials comparing
different dosing regimens of the same treatment. Each interven-
tion will be reported separately against each separate comparator.
Comparisons could be:
1. one drug versus no treatment;
2. one drug versus placebo;
3. one drug versus another drug;
4. more than one drug (combination treatment) versus no
treatment;
5. more than one drug (combination treatment) versus
placebo;
6. more than one drug (combination treatment) versus one
drug;
7. more than one drug (combination treatment) versus
another combination of drugs.
Types of outcome measures
We will not use the outcomes listed below as criteria for study
inclusion.
Primary outcomes
1. Frequency of complete haematological response (defined as
normalisation of haemoglobin concentration, reticulocyte
(immature red blood cells (RBCs)) count, and indirect (or
unconjugated] bilirubin level) at months two, six and 12.
2. Frequency of adverse events at two, six and 12 months.
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Secondary outcomes
1. Frequency of partial haematological response (defined as
improvement in haemoglobin concentration) at two, six and 12
months
2. RBC transfusion requirement after treatment (measured as
units of RBCs transfused per month or millilitres (mL) per kg
body weight) at two, six and 12 months
3. Frequency of direct anti-globulin test (DAT) positivity after
treatment at two, six and 12 months
4. Overall survival at six and 12 months
5. Relapse-free survival at six and 12 months
6. Frequency of relapse at six and 12 months
7. Quality of life (QOL) as measured by validated instruments
at 12 months
Search methods for identification of studies
Electronic searches
We will search MEDLINE (Ovid) (1946 to 2015) (Appendix 1),
EMBASE (Ovid) (1974 to 2015) (Appendix 2), LILACS (Latin
American and Caribbean Health Sciences Literature) (1982 to
2015) (Appendix 3), Cochrane Library (CENTRAL) (latest issue)
(Appendix 4), and China Journal Net (1994 to 2015) (Lefebvre
2011) (Appendix 5). The search strategies for the different elec-
tronic databases using a combination of controlled vocabulary
and text word terms are shown in the appendices (Appendix 1;
Appendix 2; Appendix 3; Appendix 4; Appendix 5).
Searching other resources
We will search the following clinical trial registries on the Internet
using the search terms “ haemolytic anaemia” or “hemolytic ane-
mia”:
1. WHO International Clinical Trials Registry Platform
(ICTRP) (http://apps.who.int/trialsearch/)
2. United States Clinical Trials Registry (https://
clinicaltrials.gov/)
3. European Union Clinical Trial Register (http://
www.clinicaltrialsregister.eu/)
We will also search conference proceedings of the following sci-
entific meetings using the search terms “ haemolytic anaemia” or
“hemolytic anemia” and “trials”:
1. Annual Meeting of American Society of Haematology
(ASH) (2004 to 2015)
2. Annual Congress of the European Haematology
Association (EHA) (2006 to 2015).
We will search reference lists of relevant articles identified in all
the searches. We will also contact authors of included studies to
enquire about additional studies. We will not apply any language
restriction in our searches.
Data collection and analysis
Selection of studies
Both review authors will independently examine identified studies
and abstracts and select studies meeting the inclusion criteria. Dis-
crepancies will be resolved by discussion. We will report the flow
of studies as per the PRISMA statement in a flow chart (Moher
2009), which includes data on the number of records identified
through database searching, number of additional records identi-
fied through other sources, number of records after duplicates re-
moved, number of records screened, number of records excluded,
number of full-text articles examined for eligibility, number of
full-text articles excluded with reasons, and numbers of studies in-
cluded in qualitative and quantitative syntheses (Higgins 2011a).
Data extraction and management
Both review authors will independently extract data using a stan-
dardised data collection form (Higgins 2011a). We will extract
data on study design and methods including study dates, location,
setting, type of study (parallel group or cross-over or other designs),
stratified randomisation variables, random sequence generation,
allocation concealment, and blinding methods. We will extract
data on participant inclusion and exclusion criteria, number of
participants in each intervention and control group, and for each
group, their demographics (age, sex, ethnicity), baseline laboratory
parameters (haemoglobin level, reticulocyte count, bilirubin level,
direct anti-globulin test (DAT) positivity), baseline transfusion re-
quirements, associated conditions and comorbidities, and previ-
ous intervention received (drug and regimen). We will extract data
on details of intervention for each group, and dropouts of each
group and follow-up duration.Wewill extract outcomes measured
in each study that match with our pre-specified outcomes. We will
also extract data on funding source and declaration of interests.
Data will be entered into ReviewManager software (RevMan 5.3)
(RevMan 2014) by one review author (APYL) and checked by the
other review author (DKLC).
Assessment of risk of bias in included studies
Overall strength and quality of evidence will be assessed by
GRADE approach as recommended by the Cochrane Handbook
for Systematic Reviews of Interventions. Both review authors will
independently assess the risk of bias of included studies with the
Cochrane ’Risk of bias’ tool (Higgins 2011b). The following do-
mains will be assessed: random sequence generation, allocation
concealment, blinding of participants, study personnel and out-
come assessors, incomplete outcome data, selective reporting, and
other sources of bias. For each domain for each study, the risk
of bias will be graded as “high”, “unclear” or “low” according to
the criteria stated in the Cochrane Handbook for Systematic Reviews
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of Interventions. Discrepancies between the review authors will be
resolved by discussion.
Measures of treatment effect
We will estimate risk ratio (RR) with 95% confidence intervals
(CI) for dichotomous outcomes. We will use hazard ratio (HR)
with 95% CI for time-to-event outcomes and mean difference
(MD) with 95% CIs for continuous outcomes. For continuous
outcomes using different scales (e.g. quality of life (QoL) data),
we will use standardised mean difference (SMD) with 95% CI
(Deeks 2011).
Unit of analysis issues
We will use appropriate unit of analysis for cluster-randomised
trials and cross-over trials according to the Cochrane Handbook for
Systematic Reviews of Interventions (Deeks 2011), if these types of
trials are found and included.
Dealing with missing data
We will contact the study authors in an attempt to acquire any
missing information. We will include all participants with inten-
tion-to-treat (ITT) analyses. For longitudinal outcome data, we
will use the last observation carried forward (LOCF) method for
imputing missed data (Higgins 2011c). In the complete absence
of continuous outcome data (including transfusion requirement
or QoL), we will not impute the data and only available data will
be analysed, while the risk of bias due to incomplete outcome
data and reporting will be assessed. For missing data on binary
outcomes (including response, relapse, DAT positivity, or adverse
events), we will assume no response, no relapse, no DAT positivity
or no adverse events. Meta-analysis of time-to-event data requires
availability of individual patient data from the original investiga-
tors (Higgins 2011a). If they are not available, we will use statis-
tical methods according to Tierney 2007.
Assessment of heterogeneity
We will use the I2 statistic to evaluate the degree of heterogeneity
of treatment effects. We will follow the guide on interpretation of
the I2 statistic suggested by the Cochrane Handbook for Systematic
Reviews of Interventions (Deeks 2011) as follows:
1. 0% to 40%: may not be important;
2. 30% to 60%: may represent moderate heterogeneity;
3. 50% to 90%: may represent substantial heterogeneity;
4. 75% to 100%: considerable heterogeneity.
We will also use theChi2 test of homogeneity to assess the strength
of evidence regarding heterogeneity. If significant heterogeneity is
present (P < 0.1), we will examine the possible reasons for het-
erogeneity. Heterogeneity can be due to the participants and out-
comes. When the participants, definition of outcomes in each
study, or the timing of each measurement of outcome in each
study is very different, we may consider the studies (even with
same intervention and comparator) too heterogeneous for pooling
of data.
Assessment of reporting biases
We will assess publication bias using a funnel plot (estimated dif-
ferences in treatment effects against their standard errors) in case 10
or more studies are identified for a given outcome (Sterne 2011).
We will try to obtain clinical trial protocols to assess for reporting
bias.
Data synthesis
With the assumption that the different studies would likely be es-
timating different, yet related, intervention effects, we will use the
random-effects model for meta-analysis to obtain the mean effect
across studies, unless the studies are so heterogeneous that pooling
data for meta-analysis is considered entirely inappropriate (Deeks
2011). If multi-arm studies are included, we will analyse multiple
intervention groups in an appropriate way that avoids arbitrary
omission of relevant groups or double counting of participants.
We will perform all analyses using the most updated version of
Review Manager (RevMan 5.3) (RevMan 2014). We will produce
’Summary of findings’ tables according to the recommendations
in the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011). Separate ’Summary of findings’ tables will be pro-
vided for each comparison (separate intervention versus separate
comparator).The pre-defined outcomes to be included are: fre-
quency of complete haematological response (defined as normali-
sation of haemoglobin concentration, reticulocyte count, and in-
direct bilirubin level) atmonths two, six and 12months, frequency
of adverse events at two, six and 12 months, overall survival at six
and 12 months, relapse-free survival at six and 12 months, RBC
transfusion requirement after treatment (measured as units of red
cells transfused per month or mL per kg body weight) at two, six
and 12 months, and QOL as measured by validated instruments
at 12 months. These tables will summarise the results for the pre-
defined outcomes of all comparisons and provide grading of the
quality of evidence for each outcome according to the GRADE
system (GRADEpro 2008; Schünemann 2011). If different tools
for measurement of QoL are used, standardised mean difference
will be used.
Subgroup analysis and investigation of heterogeneity
Wewill perform subgroup analyses (Deeks 2011) for the following
subgroups as they may have different prognosis and response to
treatment (different size of treatment effect).
1. Different age groups (children <18 years or adults >=18
years).
5Disease-modifying treatments for primary autoimmune haemolytic anaemia (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2. With or without associated conditions (such as
thrombocytopenia or neutropenia, or other autoimmune
phenomena)
3. Different degrees of anaemia (transfusion dependent or
transfusion independent)
4. Newly diagnosed versus refractory disease
We will also assess subgroup differences by examining the I2 statis-
tic and performing a Chi2 test for homogeneity across subgroup
results. In case heterogeneity is present, we will investigate the
probable reasons for heterogeneity by examining the distribution
of important participant factors between trials (age, associated
conditions, degrees of anaemia, and previous interventions) and
trial factors (randomisation concealment, blinding, dropouts, in-
tervention regimens).
Sensitivity analysis
We will perform sensitivity analysis to assess the impact of exclud-
ing studies with high risk of bias (Deeks 2011). We will also per-
form sensitivity analysis to assess the impact of excluding studies
with significant amount (> 30%) of missing outcome data.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp ANEMIA, HEMOLYTIC, AUTOIMMUNE/
2. autoimmune hemolytic anemia.mp.
3. autoimmune haemolytic anaemia.mp.
4. (haemolyt$ or hemolyt$).tw.
5. Evans.tw.
6. AIHA.tw.
7. ((agglutinin* or antibod*) adj2 cold* adj2 diseas*).tw,kf,ot.
8. or/1-7
9. randomized controlled trial.pt.









19. 17 and 18
20. 19 and 8
Appendix 2. Embase search strategy
1. exp ANEMIA, HEMOLYTIC, AUTOIMMUNE/
2. autoimmune hemolytic anemia.mp.
3. autoimmune haemolytic anaemia.mp.
4. (haemolyt$ or hemolyt$).tw.
5. Evans.tw.
6. AIHA.tw.
7. ((agglutinin* or antibod*) adj2 cold* adj2 diseas*).tw.
8. or/1-7
9. (randomi$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab.
10. RETRACTED ARTICLE/
11. or/9-10
12. (animal$ not human$).sh,hw.
13. (book or conference paper or editorial or letter or review).pt. not exp randomized controlled trial/
14. (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not exp randomized controlled
trial/
15. 11 not (12 or 13 or 14)
16. 8 and 15
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Appendix 3. LILACS search strategy
db:(“LILACS”) AND type_of_study:(“clinical_trials”) AND ((autoimmune hemolytic anemia) OR (autoimmune haemolytic anaemia)
OR hemoly* OR haemoly* OR Evans OR AIHA)
Appendix 4. CENTRAL search strategy
#1 MeSH descriptor: [Anemia, Hemolytic, Autoimmune] explode all trees
#2 autoimmune hemolytic anemia
#3 autoimmune haemolytic anaemia
#4 (haemolytic* or hemolytic*)
#5 ((agglutinin* or antibod*) near/2 cold near/2 diseas*)
#6 AIHA
#7 evans:ti,ab,kw
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7 in Trials
Appendix 5. China Journal Net search strategy
1. SU (subject) = (haemolytic anaemia)
2. TI (title) = (haemolytic anaemia)
3. KY (keyword) = (haemolytic anaemia)
4. AB (abstract) = (haemolytic anaemia)
5. (1 OR 2 OR 3 OR 4)
6. AB (abstract) = (random)
7. (5 AND 6)
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